||Pharmacology: A serine protease inhibitor inhibiting plasmin, kallikrein, thrombin as well as trypsin, which attenuates pancreatic fibrosis (1). Reduces weight gain and improves metabolism in obese rodent models (2). In clinical use (in Japan) for pancreatitis (3). Inhibits influenza virus replication in human tracheal epithelial cells (4). Reduces infection of Calu-3 lung cells by SARS-CoV-2 (responsible for COVID-19) via inhibition of the serine protease TMPRSS2 required for viral spike protein priming (5). PubChem CID: 5284360
Product is sold for research use only. Not for human therapeutic use or for medicinal purposes.
||See product label.
||Camostat Methanesulfonate;Camostat (mesylate); FOY 305; FOY-305; Foipan; CAS 59721-29-8
||494.5 g/mol. Molecular Formula: C21H26N4O8S
||4-(2-(2-(dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate, methanesulfonic acid salt
||>98% by HPLC; NMR (Conforms)
||Trypsin-like protease inhibitor. Reversibly inhibits airway epithelial sodium channel (ENaC) function (IC50 = 50 nM). Inhibits the production of TNF-alpha and monocyte chemoattractant protein-1 (MCP-1) by monocytes and disrupts proliferation of pancreatic stellate cells in a rat model of pancreatic fibrosis.
||Dry powder, off-white.
||Soluble in water or DMSO. May be dissolved in DMSO up to 50 mg/mL, or water (50 mg/mL)
||Store desiccated as supplied at -20C for up to 2 years. Store solutions at -20C for up to 1 month. Prevent multiple freeze-thaw cycles.
||See storage conditions.
||1. J Gibo et al. Lab. Invest. 2005 85:75
2. K Albarazanji et al. Am. J. Physiol. Gastrointest. Liver Physiol. 2019 316:G653
3. M Ueda et al. Nephron 2015 129:223
4. M Yamaya et al. Pulm. Pharmacol. Ther. 2015 33:66
||Biosensis SDS Camostat mesylate_4-30-2020.pdf